Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer

No abstract is available for this paper.

• Publication year

  2002

• Venue

  International Journal of Cancer

• Publication date

  2002-01-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.1614PMID 11774281
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody

  2004cited by this paper
• Tamoxifen chemoprevention of a hormone-independent tumor in the proto-neu transgenic mice model.

  2000cited by this paper
• A novel approach for nasopharyngeal carcinoma treatment uses phenylbutyrate as a protein kinase C modulator: implications for radiosensitization and EBV-targeted therapy.

  2000cited by this paper
• Activation of the p38 mitogen-activated protein kinase pathway by estrogen or by 4-hydroxytamoxifen is coupled to estrogen receptor-induced apoptosis.

  2000cited by this paper
• Estrogen hits the surface

  1999cited by this paper
• Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells.

  1999cited by this paper
• Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer

  1999cited by this paper
• Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

  1998cited by this paper
• Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.

  1998cited by this paper
• Transcriptional Upregulation of Retinoic Acid Receptor β (RARβ) Expression by Phenylacetate in Human Neuroblastoma Cells

  1998cited by this paper
• Transcriptional upregulation of retinoic acid receptor beta (RAR beta) expression by phenylacetate in human neuroblastoma cells.

  1998cited by this paper
• Estrogen Receptor Expression Activates the Transcriptional and Growth-inhibitory Response to Retinoids without Enhanced Retinoic Acid Receptor α Expression

  1998cited by this paper
• Retinoids control the expression of c-erbB receptors in breast cancer cells.

  1998cited by this paper
• Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro.

  1998cited by this paper
• Estrogen receptor expression activates the transcriptional and growth-inhibitory response to retinoids without enhanced retinoic acid receptor alpha expression.

  1998cited by this paper
• Differential modulation of transcriptional activity of oestrogen receptors by direct protein-protein interactions with retinoid receptors.

  1998cited by this paper
• Retinoic Acid Receptor α Expression Correlates with Retinoid-induced Growth Inhibition of Human Breast Cancer Cells Regardless of Estrogen Receptor Status

  1997cited by this paper
• Tumor growth inhibition, apoptosis, and Bcl-2 down-regulation of MCF-7ras tumors by sodium phenylacetate and tamoxifen combination.

  1997cited by this paper
• Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status.

  1997cited by this paper
• Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro.

  1997cited by this paper
• c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases.

  1996cited by this paper
• Up-regulation and functional role of p21Waf1/Cip1 during growth arrest of human breast carcinoma MCF-7 cells by phenylacetate.

  1996cited by this paper
• Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCaP prostate cancer cells transfected with the T24 Ha-ras oncogene.

  1996cited by this paper
• Bidirectional interactions between the estrogen receptor and the c‐erbB‐2 signaling pathways: Heregulin inhibits estrogenic effects in breast cancer cells

  1995cited by this paper
• Sodium phenylacetate induces growth inhibition and Bcl-2 down-regulation and apoptosis in MCF7ras cells in vitro and in nude mice.

  1995cited by this paper
• Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells

  1995cited by this paper
• The 8 kD product of the putative oncogene MTCP-1 is a mitochondrial protein.

  1995cited by this paper
• Antiestrogenic effects of all-trans-retinoic acid and 1,25-dihydroxyvitamin D3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms.

  1994cited by this paper
• Analogues of butyric acid that increase the expression of transfected DNAs.

  1993cited by this paper
• Responses to retinoic acid of tamoxifen-sensitive and -resistant sublines of human breast cancer cell line MCF-7.

  1992cited by this paper
• Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

  1992cited by this paper
• Phenylacetate: a novel nontoxic inducer of tumor cell differentiation.

  1992cited by this paper
• Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.

  1991cited by this paper
• Endocrine pharmacology of antiestrogens as antitumor agents.

  1990cited by this paper
• Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure.

  1990cited by this paper
• Chemopreventive efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats.

  1989cited by this paper
• Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer.

  1989cited by this paper
• Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue.

  1988cited by this paper
• Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture.

  1988cited by this paper
• Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells.

  1987cited by this paper
• The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women °clinical correlation on 547 patients

  1986cited by this paper
• Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma

  1985cited by this paper
• Binding of estradiol to purified uterine plasma membranes.

  1979cited by this paper
• Binding of 17-beta-estradiol to the outer surface and nucleus of human spermatozoa.

  1979cited by this paper
• Metabolic and proliferative responses to estrogen by hepatocytes selected for plasma membrane binding‐sites specific for estradiol‐17β

  1979cited by this paper
• Binding of 17-β-estradiol to the outer surface and nucleus of human spermatozoa

  1979cited by this paper
• Estrogen receptors in uterine plasma membrane.

  1979cited by this paper
• Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells

  1977cited by this paper

• Estrogenic control of matrix metalloproteinases: a perspective on breast tumor invasion and metastasis

  2025cites this paper
• Targeting systemic and gut microbial metabolism in ER+ breast cancer.

  2024cites this paper
• The Role of Estrogen in Ovarian Cancer and the Pathways by Which Estrogen Acts

  2023cites this paper
• Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer

  2023cites this paper
• Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER + Breast Cancer.

  2023cites this paper
• Diagnostic and differential efficacy of cyclin D1 and CA15-3 in breast cancer and benign breast tumors

  2023cites this paper
• "A Review of HER2 overexpression and somatic mutations in cancers".

  2023cites this paper
• Regulation of Bcl-2 Family Proteins in Estrogen Receptor-Positive Breast Cancer and Their Implications in Endocrine Therapy

  2022cites this paper
• Correlation of ER, PR, and HER2 at the protein and mRNA levels in Asian patients with operable breast cancer

  2022cites this paper
• Human epidermal growth factor receptor-2 and endocrine resistance in hormone-dependent breast cancer

  2022cites this paper
• Enhancement of Sensitivity to Tamoxifen by Berberine in Breast Cancer Cells by Inhibiting ER-α36 Expression

  2022cites this paper
• Hyperactivation of MAPK Induces Tamoxifen Resistance in SPRED2-Deficient ERα-Positive Breast Cancer

  2022cites this paper
• Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer

  2021cites this paper
• Microenvironmental Determinants of Breast Cancer Metastasis: Focus on the Crucial Interplay Between Estrogen and Insulin/Insulin-Like Growth Factor Signaling

  2020cites this paper
• Relative worth of estrogen and progesterone receptors as indicators of prognosis in breast cancer

  2020cites this paper
• Protons show greater relative biological effectiveness for mammary tumorigenesis with higher ERα and HER2 positive tumors relative to γ-rays in APCMin/+ mice.

  2020cites this paper
• Transportin-2 plays a critical role in nucleocytoplasmic shuttling of oestrogen receptor-α

  2020cites this paper
• Pathways to Endocrine Therapy Resistance in Breast Cancer

  2019cites this paper
• RET in breast cancer: pathogenic implications and mechanisms of drug resistance

  2019cites this paper
• Regulation of estrogen signaling and breast cancer proliferation by an ubiquitin ligase TRIM56

  2019cites this paper
• Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy

  2019cites this paper
• Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer

  2018cites this paper
• ACT001 can prevent and reverse tamoxifen resistance in human breast cancer cell lines by inhibiting NF‐κB activation

  2018cites this paper
• The human epidermal growth factor receptor 2 (HER2) in the breast cancer : from measurement to targeted treatment

  2017cites this paper
• From the Department of Oncology-Pathology , Karolinska Institutet , Stockholm , Sweden BIOLOGICAL AND THERAPEUTIC

  2017cites this paper
• New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes

  2017cites this paper
• GDNF induces RET–SRC–HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells

  2017cites this paper
• Metastatic human epidermal growth factor receptor 2-positive breast cancer: Management, challenges, and future directions.

  2016cites this paper
• Lower Beclin 1 downregulates HER2 expression to enhance tamoxifen sensitivity and predicts a favorable outcome for ER positive breast cancer

  2016cites this paper
• Minireview: The Link Between ERα Corepressors and Histone Deacetylases in Tamoxifen Resistance in Breast Cancer.

  2016cites this paper
• Evaluation of human epidermal growth factor receptor 2 (HER2) single nucleotide polymorphisms (SNPs) in normal and breast tumor tissues and their link with breast cancer prognostic factors.

  2016cites this paper
• ERβ overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ERα-positive breast cancer patients.

  2016cites this paper
• Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer

  2015cites this paper
• Factors Promoting Tamoxifen Resistance in Breast Cancer via Stimulating Breast Cancer Stem Cell Expansion.

  2015cites this paper
• Nodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis

  2015cites this paper
• Östrogenrezeptoren und ihre Bedeutung für die Prognose und Therapie des Lungenkarzinoms – neue Erkenntnisse zu einem bisher unterschätzten Mechanismus

  2015cites this paper
• Neuroprotection with Estradiol in Experimental Perinatal Asphyxia: A New Approach

  2015cites this paper
• Oestrogen-dependent regulation of gene expression by cohesin in breast cancer

  2015cites this paper
• Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.

  2015cites this paper
• Sensitization of estrogen receptor-positive breast cancer cell lines to 4-hydroxytamoxifen by isothiocyanates present in cruciferous plants

  2015influential citation
• Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.

  2015cites this paper
• From Department of Biosciences and Nutrition Karolinska Institutet, Stockholm, Sweden ESTROGENS AND LYMPHOMA GROWTH

  2015cites this paper
• POST-TRANSLATIONAL MODIFICATION OF ESTROGEN RECEPTOR ΑLPHA AND P 53 IN BREAST CANCER CELLS

  2015cites this paper
• Significance of ERβ expression in different molecular subtypes of breast cancer

  2014cites this paper
• Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance

  2014cites this paper
• 655 Val and 1170 Pro ERBB 2 SNPs in familial breast cancer risk and BRCA 1 alterations

  2014cites this paper
• Development of novel breast cancer-targeted spect imaging peptides by phage display

  2014cites this paper
• Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer.

  2014cites this paper
• The HER2-Encoded miR-4728-3p Regulates ESR1 through a Non-Canonical Internal Seed Interaction

  2014cites this paper
• Correlation between estrogen receptor β expression and the curative effect of endocrine therapy in breast cancer patients

  2014cites this paper
• Drug target strategies in breast cancer treatment: recent developments.

  2014cites this paper
• Inhibition of vacuolar H+ ATPase enhances sensitivity to tamoxifen via up-regulation of CHOP in breast cancer cells.

  2013cites this paper
• Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

  2013cites this paper
• Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.

  2013cites this paper
• Dithiiranylmethyloxy azaxanthone shows potent anti-tumor activity via suppression of HER2 expression and HER2-mediated signals in HER2-overexpressing breast cancer cells.

  2013cites this paper
• Cell cycle deregulation in breast cancer subgroups and effects on proliferation, migration and tamoxifen resistance

  2013cites this paper
• Fulvestrant-Induced Cell Death and Proteasomal Degradation of Estrogen Receptor α Protein in MCF-7 Cells Require the CSK c-Src Tyrosine Kinase

  2013cites this paper
• Sex hormone receptors in breast cancer.

  2013cites this paper
• Leptin increases HER2 protein levels through a STAT3‐mediated up‐regulation of Hsp90 in breast cancer cells

  2013cites this paper
• Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex

  2013cites this paper
• Oncogenic MUC1-C Promotes Tamoxifen Resistance in Human Breast Cancer

  2013cites this paper
• Endocrine therapy resistance: current status, possible mechanisms and overcoming strategies.

  2013cites this paper
• The Protective Effects of Estradiol on Sporadic and Inflammation-associated Colon Cancer

  2013cites this paper
• HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact.

  2013cites this paper
• The Akt/mTOR Pathway and Estrogen Receptor Phosphorylations : a crosstalk with potential to predict tamoxifen resistance in breast cancer

  2013cites this paper
• Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance

  2012cites this paper
• Hormonal resistance in breast- and prostate cancer

  2012cites this paper
• Mechanisms of resistance to endocrine therapies for breast cancer

  2012cites this paper
• Apoptosis of breast cancer cells: modulation of genes for glycoconjugate biosynthesis and targeted drug delivery.

  2012cites this paper
• Mechanisms of FGFR3 actions in endocrine resistant breast cancer

  2012cites this paper
• Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase.

  2012cites this paper
• AKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studies

  2012cites this paper
• Original Article Pharmacology and anti-tumor activity of RWJ67657, a novel inhibitor of p38 mitogen activated protein kinase

  2012cites this paper
• The development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistance.

  2012cites this paper
• Combination of post-transcriptional and post-translational down-regulation of the oestrogen receptor in breast cancer

  2011cites this paper
• Advances in the understanding of the structure and function of ER-α36,a novel variant of human estrogen receptor-alpha.

  2011cites this paper
• Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review).

  2011cites this paper
• Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression

  2011cites this paper
• Cell Cycle Regulatory Roles of Estrogen Receptor alpha (ERα) in Breast Cancer Cells

  2011cites this paper
• ERBB2 juxtamembrane domain (trastuzumab binding site) gene mutation is a rare event in invasive breast cancers overexpressing the ERBB2 gene

  2011cites this paper
• Epigenetic modulation: a novel therapeutic target for overcoming hormonal therapy resistance.

  2011cites this paper
• Biological mechanisms and clinical implications of endocrine resistance in breast cancer.

  2011cites this paper
• Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis

  2010cites this paper
• Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma

  2010cites this paper
• Growth factor activation of ErbB2/ErbB3 signaling pathways regulate the activity of Estrogen Receptors (ER)

  2010cites this paper
• Targeting endocrine resistance: is there a role for mTOR inhibition?

  2010cites this paper
• Cross talk between epidermal growth factor (EGF) receptor and extra nuclear steroid receptors in cell lines.

  2010cites this paper
• Prediction of hormone sensitivity for breast cancers

  2010cites this paper
• Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy

  2010cites this paper
• Investigations into the expression of sirtuins in breast cancer: in vivo and in vitro studies

  2010cites this paper
• Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer

  2010cites this paper
• Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways

  2010cites this paper
• G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells.

  2009cites this paper
• Ras/Raf-1/MAPK Pathway Mediates Response to Tamoxifen but not Chemotherapy in Breast Cancer Patients

  2009cites this paper
• Inhibition of HER2/estrogen Receptor Cross-Talk, Probable Relation to Prolonged Remission of Stage IV Breast Cancer: A Case Report

  2009cites this paper
• Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor α and its phosphorylation at serine 305

  2009cites this paper
• Modification of gene expression induced by siRNA targeting of estrogen receptor alpha in MCF7 human breast cancer cells.

  2009cites this paper
• Hormone resistance.

  2009cites this paper
• Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer

  2009cites this paper
• Experimental Endocrine Resistance: Concepts and Strategies

  2009cites this paper